Details of the Drug Pharmacogenomic Perturbation Atlas

Oxfendazole Drug Info

Oxfendazole; Fenbendazole sulfoxide; Synanthic; Systamex; OFDZ; Systemax; Repidose; Oxfendazolum; Oxfendazol; Synanthic (Veterinary); RS-8858; fenbendazole S-oxide; RS 8858; 5-Phenylsulfinyl-2-carbomethoxyaminobenzimidazole; Oxfendazol [INN-Spanish]; Oxfendazolum [INN-Latin]; UNII-OMP2H17F9E; HOE 8105; methyl [5-(phenylsulfinyl)-1H-benzimidazol-2-yl]carbamate; Oxfendazole [USAN:BAN:INN]; Methyl 5-(phenylsulfinyl)-2-benzimidazolecarbamate; Oxfendazole (USP/INN)

Cross-matching ID

PubChem CID

40854

ChEBI ID

CHEMBL35812

CAS Number

CAS 53716-50-0

VARIDT Drug ID

DR01557

General Information of Drug (ID: DMSNL51)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Pathways of neurodegeneration	-1.67	4.01e-2	354/475 (74.53%)	PDYN;CSF1;BRAF;...
Amyotrophic lateral sclerosis	-1.68	4.19e-2	267/364 (73.35%)	ATP5PF;NUP37;COX7C;...
Folate biosynthesis	-1.69	4.18e-2	23/26 (88.46%)	CBR1;GGH;PAH;...
Proximal tubule bicarbonate reclamation	-1.69	4.18e-2	21/23 (91.3%)	ATP1B1;FXYD2;MDH1;...
Ferroptosis	-1.76	2.13e-2	36/41 (87.8%)	ACSL6;FTL;TFRC;...
Arachidonic acid metabolism	-1.80	1.70e-2	48/61 (78.69%)	LTA4H;CBR3;PLA2G10;...
Metabolism of xenobiotics by cytochrome P450	-1.87	6.38e-3	49/77 (63.64%)	CBR1;ALDH3A1;GSTA4;...
Mineral absorption	-1.91	3.64e-3	48/60 (80%)	FTL;ATP2B3;TF;...
Ribosome	-1.92	4.25e-3	113/158 (71.52%)	RPL6;RPL4;RPS14;...
Glutathione metabolism	-1.98	5.10e-3	43/57 (75.44%)	GSTA4;GSTM5;GSTK1;...
Mitophagy	-1.99	2.13e-3	56/68 (82.35%)	MITF;JUN;TFEB;...
Parkinson disease	-2.01	2.83e-3	176/249 (70.68%)	KIF5A;ITPR2;CAMK2A;...
Collecting duct acid secretion	-2.09	0.00e+0	22/27 (81.48%)	SLC4A1;ATP6V1G1;ATP6V1B2;...
Nitrogen metabolism	-2.27	0.00e+0	16/17 (94.12%)	GLUD1;CA4;GLUD2;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	3H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	10uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H